A weekly podcast exploring medicine 4.0 as we launch into the 21st Century of health. Join us as we highlight the science and investment case for the different diseases and conditions that life sciences companies are trying to diagnose and cure.
A weekly podcast exploring medicine 4.0 as we launch into the 21st Century of health. Join us as we highlight the science and investment case for the different diseases and conditions that life sciences companies are trying to diagnose and cure.
Moderna and BioNTech are getting all of the attention with their phase 3 clinical trials for lung cancer and melanoma. But someone else is already further ahead.
French company Ose Immunotherapeutics has already done a phase 3 study for non small cell lung cancer, and if the final run of work confirms that data it will have the first cancer vaccine on the market in 2028.
And it's results like those emerging from Ose that are inspiring investors to start getting set for a cancer vaxxed future.
In our final episode of VAXXED we feature OneVentures partner Dr. Jeannie Joughin and Ose Immunotherapeutics CEO Nicolas Poirier.
Produced by Rachel Williamson and Charis Palmer. Music and effect credits to Ziso, Inspector J, Seth Parson and Boom Library.
